Drug‐Eluting Porous Embolic Microspheres for Trans‐Arterial Delivery of Dual Synergistic Anticancer Therapy for the Treatment of Liver Cancer
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202301548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Benzion Amoyav und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Institute for Drug Research, School of Pharmacy, The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Research Council.
Abstract (Originalsprache)
Blockage of blood supply while administering chemotherapy to tumors, using trans‐arterial chemoembolization (TACE), is the most common treatment for intermediate and advanced‐stage unresectable Hepatocellular carcinoma (HCC). However, HCC is characterized by a poor prognosis and high recurrence rates (≈30%), partly due to a hypoxic pro‐angiogenic and pro‐cancerous microenvironment. This study investigates how modifying tissue stress while improving drug exposure in target organs may maximize the therapeutic outcomes. Porous degradable polymeric microspheres (MS) are designed to obtain a gradual occlusion of the hepatic artery that nourishes the liver, while enabling efficient drug perfusion to the tumor site. The fabricated porous MS are introduced intrahepatically and designed to release a combination therapy of Doxorubicin (DOX) and Tirapazamine (TPZ), which is a hypoxia‐activated prodrug. Liver cancer cell lines that are treated with the combination therapy under hypoxia reveal a synergic anti‐proliferation effect. An orthotopic liver cancer model, based on N1‐S1 hepatoma in rats, is used for the efficacy, biodistribution, and safety studies. Porous DOX‐TPZ MS are very effective in suppressing tumor growth in rats, and induction tissue necrosis is associated with high intratumor drug concentrations. Porous particles without drugs show some advantages over nonporous particles, suggesting that morphology may affect the treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Institute for Drug Research, School of Pharmacy, The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel.
- Department of Medical Imaging-Interventional Radiology, Hadassah Medical Center, Jerusalem, 911200, Israel.
- Department of General Surgery, Kaplan Medical Center, Affiliated to Hebrew University Jerusalem, Rehovot, 76100, Israel.
- Authority for Biological and Biomedical Models, Hadassah Medical Center, Jerusalem, 911200, Israel.
ORCID-Profile: Ofra Benny
Förderung
- European Research Council
Zitieren
APA
Amoyav, B., Bloom, A. I., Goldstein, Y., Miller, R., Sharam, M., Fluksman, A., & Benny, O. (2023). Drug‐Eluting Porous Embolic Microspheres for Trans‐Arterial Delivery of Dual Synergistic Anticancer Therapy for the Treatment of Liver Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202301548
Vancouver
Amoyav B, Bloom AI, Goldstein Y, Miller R, Sharam M, Fluksman A, et al. Drug‐Eluting Porous Embolic Microspheres for Trans‐Arterial Delivery of Dual Synergistic Anticancer Therapy for the Treatment of Liver Cancer. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202301548
BibTeX
@article{Amoyav2023,
author = {Amoyav, Benzion and Bloom, Allan I and Goldstein, Yoel and Miller, Rafael and Sharam, Mariana and Fluksman, Arnon and Benny, Ofra},
title = {Drug‐Eluting Porous Embolic Microspheres for Trans‐Arterial Delivery of Dual Synergistic Anticancer Therapy for the Treatment of Liver Cancer},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202301548}
}
EUVIMED